![ECCO 2022 Insights: Treatment developments for inflammatory bowel disease (IBD) and rheumatology - European Medical Journal ECCO 2022 Insights: Treatment developments for inflammatory bowel disease (IBD) and rheumatology - European Medical Journal](https://embed-ssl.wistia.com/deliveries/f0344b3407ed4e8e865edf5a54b4ad9a/file..jpg?image_crop_resized=1920x1080)
ECCO 2022 Insights: Treatment developments for inflammatory bowel disease (IBD) and rheumatology - European Medical Journal
![Beta-Cell Fragility As a Common Underlying Risk Factor in Type 1 and Type 2 Diabetes: Trends in Molecular Medicine Beta-Cell Fragility As a Common Underlying Risk Factor in Type 1 and Type 2 Diabetes: Trends in Molecular Medicine](https://www.cell.com/cms/attachment/673eb758-b854-4bd1-853d-2b5359d8eefd/gr1_lrg.jpg)
Beta-Cell Fragility As a Common Underlying Risk Factor in Type 1 and Type 2 Diabetes: Trends in Molecular Medicine
![ECCO 2016: Professor Séverine Vermeire (Leuven, Belgium) discusses new patient guidelines for Crohn's disease and ulcerative colitis which were released at this year's 11th Congress of ECCO in Amsterdam, and Helen Terry ( ECCO 2016: Professor Séverine Vermeire (Leuven, Belgium) discusses new patient guidelines for Crohn's disease and ulcerative colitis which were released at this year's 11th Congress of ECCO in Amsterdam, and Helen Terry (](https://medicalupdateonline.com/wp-content/uploads/2016/05/ECCO-2016-Part-1-ECCO-EFCCA-Pat-Guidelines.jpg)
ECCO 2016: Professor Séverine Vermeire (Leuven, Belgium) discusses new patient guidelines for Crohn's disease and ulcerative colitis which were released at this year's 11th Congress of ECCO in Amsterdam, and Helen Terry (
![Retail India - Footwear brand ECCO Continued Its Strong Performance in 2019 - But Covid-19 Challenges the 2020 result Retail India - Footwear brand ECCO Continued Its Strong Performance in 2019 - But Covid-19 Challenges the 2020 result](https://indian-retailer.s3.ap-south-1.amazonaws.com/s3fs-public/2020-04/shhoee.jpg)